PD-1 AND PD-L1 INHIBITOR MARKET ANALYSIS

PD-1 and PD-L1 Inhibitor Market Size and Trends

The PD-1 and PD-L1 inhibitor market is estimated to be valued at USD 52.51 Bn in 2024 and is expected to reach USD 170.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 18.3% from 2024 to 2031.

To learn more about this report, request sample copy

The market is witnessing positive growth due to increasing demand for immunotherapies for treatment of various cancer types. PD-1 and PD-L1 inhibitors have demonstrated high efficacy in treatment of lung cancer, kidney cancer, melanoma and other cancers. These drugs have better side effect profile compared to conventional chemotherapy. Ongoing clinical trials evaluating efficacy of PD-1 and PD-L1 inhibitors for new cancer indications such as gastric cancer, cervical cancer and pancreatic cancer are also boosting the market. Moreover, approval of combination therapies of PD-1 and PD-L1 inhibitors with other immunotherapies is further driving the market growth. However, high cost of therapy is one of the factors hindering widespread adoption of PD-1 and PD-L1 inhibitors.

Increase in cancer incidence

The rise in incidence/prevalence of cancer across the globe is expected to boost growth of the global PD-1 and PD-L1 inhibitor market during the forecast period. For instance, PD-1/PD-L1 inhibitors are important immune checkpoint inhibitors (ICIs) used as front-line treatments for several types of cancer. According to the World Health Organization (WHO) February 2022 press release, cancer was one of the leading causes of death worldwide, accounting for around ten million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. Thus, there is an increase in demand for PD-1 and PD-L1 inhibitors worldwide.

Growing geriatric population around the world is expected to augment growth of the global PD-1 and PD-L1 inhibitor market during the forecast period. For instance, according to the Union for International Cancer Control (UICC), elderly (people aged 65 years and more) are 11 times more likely to develop cancer, compared to younger people. According to the United Nations January 2023 press release, there are over 761 million people aged 65 or older in 2021, a number that is projected to reach 1.6 billion by 2050.